Galderma SA - Company Profile

Powered by

All the data and insights you need on Galderma SA in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Galderma SA Strategy Report

  • Understand Galderma SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Galderma SA: Overview

Select Item

Related keylists

Galderma SA (Galderma) develops and markets medical and consumer skin health products. The company provides prescription drugs and aesthetic solutions for the treatment of various skin conditions such as acne, rosacea, psoriasis and steroid-responsive dermatoses, nail mycosis, pigmentary disorders, skin cancer, atopic dermatitis, and sun protection among others. Its major brands include Epiduo, Differin, Oracea, Loceryl, Metvix, Azzalure/Dysport, Mirvaso, Soolantra, Restylane, Cetaphil, and Emervel. The company has its research and development centers and manufacturing sites in Asia-Pacific, the Middle East, Europe, Africa, and North and Latin America. Galderma is headquartered in Zug, Switzerland.

 Gain a 360-degree view of Galderma SA and make more informed decisions for your business Gain a 360-degree view of Galderma SA and make more informed decisions for your business Find out more
Headquarters Switzerland
Address Zahlerweg 10, Zug, 6300
Website www.galderma.com
Telephone 41 21 6427800
No of Employees 5,700
Industry Pharmaceuticals and Healthcare
Revenue (2022) $3.8B
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Galderma SA premium industry data and analytics

340+

Clinical Trials

Determine Galderma SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

100+

Catalyst Calendar

Proactively evaluate Galderma SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Galderma SA’s relevant decision makers and contact details.

50+

Marketed Drugs

Understand Galderma SA’s commercialized product portfolio to stay one step ahead of the market.

18+

Pipeline Drugs

Identify which of Galderma SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

17+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Galderma SA (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Galderma SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Categories: Epiduo
Prescription Differin
Consumer Mirvaso
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Galderma SA portfolio and identify potential areas for collaboration Understand Galderma SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In June, the company received FDA approval for its hyaluronic acid filler, Restylane Eyelight.
2023 Stock Listings/IPO In March, the company announced its plans to raise EUR3 billion in an IPO.
2023 New Products/Services In March, the company launched an aesthetic visualization tool, FACE by Galderma.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Galderma SA Bausch Health Companies Inc Almirall Hermal GmbH Aesthetic Medical International Holdings Group Ltd Merz Aesthetics
Headquarters Switzerland Canada Germany China United States of America
City Zug Laval Reinbek Shenzhen Raleigh
State/Province - Quebec Schleswig-Holstein Guangdong North Carolina
No. of Employees 5,700 19,900 299 1,167 -
Entity Type Private Public Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Flemming Ornskov Chief Executive Officer Senior Management 2019 -
Thomas Dittrich Chief Financial Officer Senior Management 2019 -
Christian Marcoux Chief Communications Officer Senior Management 2020 -
Nakisa Serry General Counsel; Chief Compliance Officer Senior Management 2020 -
Kristen Slaoui Chief Corporate Development Officer Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Galderma SA key executives to enhance your sales strategy Gain insight into Galderma SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward